Wide-Area Parasystemic Treatment of Skin Related Conditions

• US 20100004582A1
• Filed: 10/25/2007
• Published: 01/07/2010
• Est. Priority Date: 10/25/2006
• Status: Abandoned Application

• Current Assignee: Pantec Biosolutions AG
• Original Assignee: Pantec Biosolutions AG
• Inventors: Zech, Nicolas, Böhler, Christof, Bragagna, Thomas
• Application Number:
  US12/447,030
• Publication Number:
  US 20100004582A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61B 18/203 applying laser energy to the outside of the body
• CPC Class Codes: A61B 2017/00477 Coupling A61B2017/0046 takes precedence
• CPC Class Codes: A61B 2017/00765 Decreasing the barrier function of skin tissue by radiated energy, e.g. using ultrasound, using laser for skin perforation
• CPC Class Codes: A61B 2018/00452 Skin
• CPC Class Codes: A61B 2018/0047 Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
• CPC Class Codes: A61B 2018/20359 by movable mirrors, e.g. galvanometric
• CPC Class Codes: A61B 2218/008 for smoke evacuation
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

Use of an immunomodulatory, immunostimulatory, or immunosuppressive drug in the manufacture of a medicament for treatment of a skin related disease or disorder, wherein the drug is formulated for topical administration to porated skin having a plurality of pores with predetermined geometry such that the concentration of the drug in combination with the predetermined geometry of the pores are effective in treatment of the skin related disease or disorder. The method of facilitating treatment of a skin related disease or disorder, comprising providing information that a drug is effective in treatment of the skin related disease or disorder; providing information to apply the drug to an area of porated skin comprising a plurality of pores; wherein the information specifies that the area is equal or greater than 1 cm²; wherein the information further specifies that at least some of the plurality of pores have a predetermined geometry; and wherein the predetermined geometry is effective to substantially prevent systemic administration of the drug.

Claims

1. A method of treating a skin related disease or skin related disorder comprising:

topically applying to a porated skin a formulation for topical administration wherein the formulation comprises at a concentration an immunomodulatory, immunostimulatory, or immunosuppressive drug;

wherein the porated skin has a plurality of pores with predetermined geometry such that the concentration of the drug in combination with a predetermined geometry of the plurality of pores are effective in treatment of the skin related disease or skin related disorder.

2. The method of claim 1 wherein the skin related disease or disorder is a skin graft rejection, a disease or disorder in which skin is involved in an at least mediatory role, a limb transplant rejection, or an autoimmune disease.

3. The method of claim 1 wherein the predetermined geometry controls at least one of inner pore surface, diameter of the pore, time to pore re-closure, and determination of delivery depth.

4. The method of claim 1 wherein the plurality of pores have a geometry such that topical administration will not result in or strongly reduce the systemic delivery of the drug.

5. The method of claim 1 wherein the drug is conjugated to a moiety that reduces or prevents entry of the drug into systemic circulation.

6. A method of using a porator to create an area of porated skin of equal or greater than 1 cm², for a wide area administration of a drug through the skin.

7. The method of claim 6, wherein the porator is a laser porator adapted to direct a pulsed laser beam onto the skin to create a plurality of pores, and where the laser porator is adapted to hit at least a single one of the plurality of pores at least twice.

8. A method of facilitating treatment of a skin related disease or disorder, comprising:

providing information that a drug is effective in treatment of the skin related disease or disorder;

providing information to apply the drug to an area of porated skin comprising a plurality of pores;

wherein the information specifies that the area is equal or greater than 1 cm²;

wherein the information further specifies that at least some of the plurality of pores have a predetermined geometry; and

wherein the predetermined geometry is effective to substantially prevent systemic administration of the drug.

9. The method of claim 8 wherein the skin related disease or disorder is responsive to treatment with an immunomodulatory, immunostimulatory, or immunosuppressive drug.

10. The method of claim 8 wherein the skin related disease or disorder is a skin graft rejection or limb transplant rejection.

11. The method of claim 8 wherein the skin related disease or disorder is an autoimmune disease, an allergic reaction, or a disease or disorder in which skin is involved in an at least mediatory role.

12. The method of claim 8 wherein the drug is selected from the group consisting of an immunomodulatory drug, an immunostimulatory drug, an immunosuppressive drug, an anti-inflammatory drug, and a steroidal drug, optionally conjugated to a moiety that reduces or prevents entry of the drug into systemic circulation.

13. The method of claim 8 wherein the area is between 1 cm² and 25 cm², or between 25 cm² and 100 cm².

14. The method of claim 8 wherein the pores are formed in a manner effective to reduce or prevent scar formation.

15. The method of claim 8 wherein the number of pores in the area of porated skin is between 10 and 100,000.

16. The method of claim 8 wherein the predetermined geometry is at least in part a function of the drug.

17. The method of claim 8 wherein the predetermined geometry comprises at least one of determination of inner pore surface, determination of time to pore re-closure, pore depth, and determination of delivery depth.

18. A kit comprising:

(a) a drug that is effective in treatment of the skin related disease or skin related disorder, and (b) an instruction to apply the drug to an area of porated skin comprising a plurality of pores, wherein the information specifies that the area is equal or greater than 1 cm², and wherein the information further specifies that at least some of the plurality of pores have a predetermined geometry that is effective to prevent systemic administration of the drug.

19. The kit of claim 18 wherein the skin related disease or disorder is responsive to treatment with an immunomodulatory, immunostimulatory, or immunosuppressive drug.

20. The kit of claim 18 wherein the skin related disease or skin related disorder is a skin graft rejection, a disease or disorder in which skin is involved in an at least mediatory role, a limb transplant rejection, or an autoimmune disease.

21. The kit of claim 18 wherein the instruction further provides laser poration parameter that determine the predetermined geometry, and wherein the pores are formed in a manner to reduce or prevent scar formation.

22. A method of treating a skin related disease or skin related disorder, comprising:

forming an area of porated skin comprising a plurality of pores, wherein the area is equal or greater than 1 cm², and wherein at least some of the plurality of pores have a predetermined geometry;

wherein the predetermined geometry is at least in part a function of the drug and controls at least one of inner pore surface, time to pore re-closure, and delivery depth; and

applying the drug to the area of porated skin.

23. The method of claim 22 wherein the step of forming the area of porated skin comprises laser ablation at a wavelength of at least 2500 nm.

24. The method of claim 22 wherein the skin related disease or skin related disorder is responsive to treatment with an immunomodulatory, immunostimulatory, or immunosuppressive drug.

25. The method of claim 22 wherein the skin related disease or skin related disorder is a skin graft rejection, a disease or disorder in which skin is involved in an at least mediatory role, limb transplant rejection, or a skin autoimmune disease.